Covis pharma

AstraZeneca Sells COPD Drug Rights to Covis

AstraZeneca has agreed to transfer its global rights to two drugs for treating patients with chronic obstructive pulmonary disease (COPD) to Switzerland’s Covis Pharma for $270 million. The transaction is expected to close in the fourth quarter of 2021.

News

Covis Buys US Biotech Amag Pharmaceuticals

Specialty pharma company Covis has agreed to buy US-based Amag Pharmaceuticals, boosting its portfolio of therapies for life-threatening conditions and chronic illnesses.

News

AstraZeneca Sells Synagis Rights to Sobi

Top-Feature

Nova-Institut GmbH

Leading Transformation

Virtual Event

Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

AstraZeneca

Covis pharma

AstraZeneca Sells COPD Drug Rights to Covis

Covis Buys US Biotech Amag Pharmaceuticals

AstraZeneca Sells Synagis Rights to Sobi

Top-Feature

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Brenntag Downsizes Management Board, Retains Both Divisions

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Anchored in Sustainability

Driving Sustainability Through Collaboration

Leading the way. Driving results.

API Manufacturing

Leading Transformation

Virtual Event

Downstream Purification

Newsletter & e-edition